RA Capital Management L.P. Has $56.21 Million Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)

RA Capital Management L.P. increased its holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 1.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,105,213 shares of the biotechnology company's stock after buying an additional 61,457 shares during the quarter. RA Capital Management L.P. owned about 9.05% of Astria Therapeutics worth $56,208,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Rhumbline Advisers raised its holdings in Astria Therapeutics by 4.1% during the second quarter. Rhumbline Advisers now owns 65,375 shares of the biotechnology company's stock worth $595,000 after purchasing an additional 2,556 shares in the last quarter. Quest Partners LLC raised its stake in shares of Astria Therapeutics by 3,310.6% in the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company's stock worth $29,000 after buying an additional 3,112 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Astria Therapeutics by 6.9% during the second quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company's stock valued at $1,266,000 after buying an additional 8,965 shares in the last quarter. PDT Partners LLC acquired a new position in Astria Therapeutics during the third quarter worth about $140,000. Finally, SG Americas Securities LLC bought a new stake in Astria Therapeutics in the third quarter worth about $155,000. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Stock Performance

NASDAQ ATXS traded down $0.16 on Thursday, reaching $9.98. The stock had a trading volume of 989,144 shares, compared to its average volume of 599,209. Astria Therapeutics, Inc. has a 1 year low of $4.87 and a 1 year high of $16.90. The business has a 50 day moving average price of $11.01 and a 200 day moving average price of $10.65.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Wedbush reaffirmed an "outperform" rating and issued a $22.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Oppenheimer upped their price target on Astria Therapeutics from $26.00 to $28.00 and gave the company an "outperform" rating in a report on Thursday, November 14th. HC Wainwright restated a "buy" rating and issued a $16.00 target price on shares of Astria Therapeutics in a report on Thursday, November 14th. Finally, Evercore ISI raised Astria Therapeutics to a "strong-buy" rating in a report on Wednesday, August 14th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $25.60.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.